Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04JCN
|
||||
| Former ID |
DAP000069
|
||||
| Drug Name |
Pergolide
|
||||
| Synonyms |
Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Approved | [1], [2] | ||
| Therapeutic Class |
Antiparkinson Agents
|
||||
| Company |
Valeant Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H26N2S
|
||||
| InChI |
InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1
|
||||
| InChIKey |
YEHCICAEULNIGD-MZMPZRCHSA-N
|
||||
| CAS Number |
CAS 66104-22-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9629, 7980280, 8180418, 11335617, 11360856, 11364541, 11367103, 11369665, 11372755, 11374547, 11377827, 11461828, 11466323, 11467443, 11485835, 11486185, 11489786, 11491403, 11492650, 11495461, 14825868, 14874447, 22390536, 24263009, 26754330, 26754331, 34712767, 46507604, 47588942, 47588943, 47662223, 47736415, 47736416, 47810696, 47810697, 47885355, 48110404, 48259176, 48416397, 48484161, 49698421, 49965528, 50109822, 50586184, 57288804, 57313147, 85788351, 85789354, 90341767, 92308734
|
||||
| SuperDrug ATC ID |
N04BC02
|
||||
| SuperDrug CAS ID |
cas=066104221
|
||||
| Target and Pathway | |||||
| Target(s) | Dopamine D1 receptor | Target Info | Modulator | [3] | |
| D(2) dopamine receptor | Target Info | Modulator | [3] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Morphine addiction | |||||
| Alcoholismhsa04015:Rap1 signaling pathway | |||||
| Alcoholism | |||||
| PANTHER Pathway | Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| PathWhiz Pathway | Dopamine Activation of Neurological Reward System | ||||
| Reactome | Dopamine receptors | ||||
| G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 48). | ||||
| REF 2 | Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.